var data={"title":"Autoimmune hepatitis: Disease classification","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Autoimmune hepatitis: Disease classification</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/contributors\" class=\"contributor contributor_credentials\">Michael A Heneghan, MD, MMedSc, FRCPI</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/contributors\" class=\"contributor contributor_credentials\">Sanjiv Chopra, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/contributors\" class=\"contributor contributor_credentials\">Kristen M Robson, MD, MBA, FACG</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 24, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autoimmune hepatitis is a chronic hepatitis which can progress to cirrhosis. It is characterized by autoimmune features, hyperglobulinemia, and the presence of circulating autoantibodies. Most cases respond to therapy with immunomodulating drugs. (See <a href=\"topic.htm?path=autoimmune-hepatitis-treatment\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Treatment&quot;</a>.)</p><p>Since it was first described in the 1950s, this disorder has been known by a variety of terms, including active chronic hepatitis, chronic active hepatitis, chronic aggressive hepatitis, lupoid hepatitis, plasma cell hepatitis, and, most commonly, autoimmune chronic active hepatitis. In 1992, the International Autoimmune Hepatitis Group recommended autoimmune hepatitis as the most appropriate and least redundant term for this disease [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Autoimmune hepatitis is characterized by considerable heterogeneity, as illustrated by the variety of clinical features, histologic findings, immunogenetic phenotypes, and circulating autoantibodies (see <a href=\"topic.htm?path=autoimmune-hepatitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Clinical manifestations and diagnosis&quot;</a>). Since the discovery of a distinct form of autoimmune hepatitis seen primarily in children and young adults that is generally characterized by antibodies to a specific cytochrome P450 (IID6) located in liver and kidney microsomes [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/2\" class=\"abstract_t\">2</a>], a classification of autoimmune hepatitis based upon circulating autoantibodies has been proposed.</p><p>Although extensions of this autoantibody-based classification have been proposed from time to time, none has proven to provide a valid, clinically useful classification for predicting disease course or response to treatment. In addition, there is little evidence to support a role for these antibodies in the pathogenesis of this disorder. (See <a href=\"topic.htm?path=autoimmune-hepatitis-pathogenesis\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Pathogenesis&quot;</a>.)</p><p>This topic review will discuss the classification of autoimmune hepatitis, while its diagnosis is presented separately (see <a href=\"topic.htm?path=autoimmune-hepatitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Clinical manifestations and diagnosis&quot;</a>). This topic is also discussed in a guideline issued by the American Association for the Study of Liver Diseases (AASLD). This guideline [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/3\" class=\"abstract_t\">3</a>] can be accessed through <a href=\"http://www.aasld.org/publications/practice-guidelines-0&amp;token=t2BaFoyGieajctrWibOej0/u85V51jE0W04MnsGmcTfhTU1FFI2vFHKxHBZZ5NifMn+fAzNy8UtrnaSPONeYkw==&amp;TOPIC_ID=3663\" target=\"_blank\" class=\"external\">the AASLD website</a>.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">CLASSIFICATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The current classification of autoimmune hepatitis according to the type of autoantibodies present is depicted in the table (<a href=\"image.htm?imageKey=GAST%2F65135\" class=\"graphic graphic_table graphicRef65135 \">table 1</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/3,4\" class=\"abstract_t\">3,4</a>]. The characteristics of the major antibodies are discussed elsewhere (see <a href=\"topic.htm?path=autoimmune-hepatitis-serologic-markers\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Serologic markers&quot;</a>). Two major forms have been described, type 1 and type 2.</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Type 1 autoimmune hepatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type 1, or classic autoimmune hepatitis, is characterized by circulating antibodies to nuclei (ANA) <span class=\"nowrap\">and/or</span> smooth muscle (ASMA); the latter are thought to be reflective of more specific anti-actin antibodies (AAA). ASMA titers of 1:320 or greater generally reflect the presence of AAA. Immunoglobulin G (IgG) anti F actin AAA measured by ELISA appear to be more sensitive than ASMA measured by immunofluorescence [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/5\" class=\"abstract_t\">5</a>], but in some cases ASMA are found in the absence of AAA.</p><p>In addition, antibodies to soluble liver antigens (SLA; also referred to as anti-liver pancreas antibodies) occur in approximately 10 to 30 percent of patients with type 1 and type 2 autoimmune hepatitis [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/6\" class=\"abstract_t\">6</a>]. When SLA antibodies were first described, they were incorrectly thought to represent a distinct third form of autoimmune hepatitis (sometimes referred to as type 3 autoimmune hepatitis) [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/7\" class=\"abstract_t\">7</a>]. However, it now appears that a variety of antibodies appear in the two major forms of the disease, but SLA antibodies are the most specific. (See <a href=\"topic.htm?path=autoimmune-hepatitis-pathogenesis\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Pathogenesis&quot;</a>.)</p><p>Other antibodies described in type 1 autoimmune hepatitis include those directed against DNA (including double-stranded DNA), Saccharomyces cerevisiae (ASCA), a plasma-membrane sulfatide, the nuclear envelope proteins lamins A and C, a number of cytoskeleton antigens, and antineutrophil cytoplasmic antibodies (ANCA), which characterize primary sclerosing cholangitis and inflammatory bowel disease [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/8-11\" class=\"abstract_t\">8-11</a>]. ANCA are commonly present in type 1 but not type 2 autoimmune hepatitis; they have a perinuclear antineutrophil cytoplasmic antibody (pANCA) pattern on immunofluorescence and are directed against a myeloid 50 kilodalton nuclear envelope protein rather than myeloperoxidase with typical ANCA. (See <a href=\"topic.htm?path=clinical-spectrum-of-antineutrophil-cytoplasmic-autoantibodies\" class=\"medical medical_review\">&quot;Clinical spectrum of antineutrophil cytoplasmic autoantibodies&quot;</a>.) On occasion, they appear as isolated antibodies [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/11\" class=\"abstract_t\">11</a>].</p><p>Circulating antibodies against the liver-specific asialoglycoprotein receptor are found in a large percentage of European, Asian, and North American patients with autoimmune hepatitis. At present, these antibodies serve primarily as a research tool [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/12\" class=\"abstract_t\">12</a>].</p><p>On occasion, antimitochondrial antibodies (AMA), which are generally seen in primary biliary cirrhosis, accompany ANA, SLA, <span class=\"nowrap\">and/or</span> ASMA in autoimmune hepatitis [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/4,13\" class=\"abstract_t\">4,13</a>]. In contrast, the isolated presence of AMA almost always signifies primary biliary cirrhosis, except in those rare instances in which an overlap syndrome occurs [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/4,13\" class=\"abstract_t\">4,13</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Type 2 autoimmune hepatitis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Type 2 autoimmune hepatitis is defined by the presence of antibodies to <span class=\"nowrap\">liver/kidney</span> microsomes (ALKM-1), which are directed at an epitope of CYP2D6 (cytochrome P450IID6), <span class=\"nowrap\">and/or</span> antibodies to a liver cytosol antigen (ALC-1 or LC1) and to SLA [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/2,14,15\" class=\"abstract_t\">2,14,15</a>] (see <a href=\"topic.htm?path=autoimmune-hepatitis-serologic-markers\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Serologic markers&quot;</a>). On occasion, type 2 autoimmune hepatitis may be marked exclusively by ALC-1. Rarely, ALKM-3 antibodies (seen in chronic delta hepatitis) are seen [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/7\" class=\"abstract_t\">7</a>].</p><p>ALKM-2 antibodies, seen in ticrynafen-induced hepatitis, are not characteristic of type 2 autoimmune hepatitis [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/16\" class=\"abstract_t\">16</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Overlap syndromes</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with variant forms of autoimmune hepatitis have clinical and serologic findings of autoimmune hepatitis plus features of other forms of chronic liver disease, particularly primary biliary cirrhosis or primary sclerosing cholangitis. The taxonomy of these variants (also referred to as overlap syndromes) is controversial. Studies in children describe an overlap syndrome referred to as autoimmune sclerosing cholangitis in a higher proportion of patients than that seen in adults. (See <a href=\"topic.htm?path=autoimmune-hepatitis-variants-definitions-and-treatment\" class=\"medical medical_review\">&quot;Autoimmune hepatitis variants: Definitions and treatment&quot;</a>.)</p><p>There are also autoimmune conditions associated with elevated blood <span class=\"nowrap\">and/or</span> tissue levels of IgG4. Recognized IgG4-associated diseases include pancreatitis and cholangitis. IgG4-associated autoimmune hepatitis has also been proposed, but whether it represents a distinct entity is not yet clear [<a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/17\" class=\"abstract_t\">17</a>].</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.) </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Beyond the Basics topics (see <a href=\"topic.htm?path=autoimmune-hepatitis-beyond-the-basics\" class=\"medical medical_patient\">&quot;Patient education: Autoimmune hepatitis (Beyond the Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The current classification of autoimmune hepatitis according to the type of autoantibodies present is depicted in the table (<a href=\"image.htm?imageKey=GAST%2F65135\" class=\"graphic graphic_table graphicRef65135 \">table 1</a>). The characteristics of the major antibodies are discussed elsewhere (see <a href=\"topic.htm?path=autoimmune-hepatitis-serologic-markers\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Serologic markers&quot;</a>). Two major forms of autoimmune hepatitis have been described, type 1 and type 2.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type 1, or classic autoimmune hepatitis, is characterized by circulating antinuclear antibodies (ANA) <span class=\"nowrap\">and/or</span> anti-smooth muscle antibodies (ASMA) and anti-actin antibodies (AAA), although other autoantibodies may be present.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Type 2 autoimmune hepatitis is defined by the presence of antibodies to <span class=\"nowrap\">liver/kidney</span> microsomes (ALKM-1), which are directed at an epitope of CYP2D6 (cytochrome P450IID6), <span class=\"nowrap\">and/or</span> antibodies to a liver cytosol antigen (ALC-1 or LC1).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with variant forms of autoimmune hepatitis have clinical and serologic findings of autoimmune hepatitis plus features of other forms of chronic liver disease, particularly primary biliary cirrhosis or primary sclerosing cholangitis. (See <a href=\"topic.htm?path=autoimmune-hepatitis-variants-definitions-and-treatment\" class=\"medical medical_review\">&quot;Autoimmune hepatitis variants: Definitions and treatment&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of autoimmune hepatitis is discussed separately. (See <a href=\"topic.htm?path=autoimmune-hepatitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Autoimmune hepatitis: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H19572391\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The author and UpToDate would like to thank Dr. Edward Krawitt, who contributed to earlier versions of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/1\" class=\"nounderline abstract_t\">Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18:998.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/2\" class=\"nounderline abstract_t\">Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of &quot;autoimmune&quot; hepatitis. Hepatology 1987; 7:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/3\" class=\"nounderline abstract_t\">Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51:2193.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/4\" class=\"nounderline abstract_t\">Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354:54.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/5\" class=\"nounderline abstract_t\">Frenzel C, Herkel J, L&uuml;th S, et al. Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis. Am J Gastroenterol 2006; 101:2731.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/6\" class=\"nounderline abstract_t\">Czaja AJ, Carpenter HA, Manns MP. Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 1993; 105:1522.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/7\" class=\"nounderline abstract_t\">European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis. J Hepatol 2015; 63:971.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/8\" class=\"nounderline abstract_t\">Reddy KR, Colombel JF, Poulain D, Krawitt EL. Anti-Saccharomyces cerevisiae antibodies in autoimmune liver disease. Am J Gastroenterol 2001; 96:252.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/9\" class=\"nounderline abstract_t\">Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997; 25:1105.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/10\" class=\"nounderline abstract_t\">Terjung B, Spengler U, Sauerbruch T, Worman HJ. &quot;Atypical p-ANCA&quot; in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000; 119:310.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/11\" class=\"nounderline abstract_t\">Krawitt EL. Sudden jaundice with isolated atypical perinuclear antineutrophil cytoplasmic antibodies. Ann Intern Med 1999; 131:796.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/12\" class=\"nounderline abstract_t\">Treichel U, McFarlane BM, Seki T, et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994; 107:799.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/13\" class=\"nounderline abstract_t\">O'Brien C, Joshi S, Feld JJ, et al. Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis. Hepatology 2008; 48:550.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/14\" class=\"nounderline abstract_t\">Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116:643.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/15\" class=\"nounderline abstract_t\">Bridoux-Henno L, Maggiore G, Johanet C, et al. Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin Gastroenterol Hepatol 2004; 2:825.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/16\" class=\"nounderline abstract_t\">Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994; 344:578.</a></li><li><a href=\"https://www.uptodate.com/contents/autoimmune-hepatitis-disease-classification/abstract/17\" class=\"nounderline abstract_t\">Umemura T, Zen Y, Nakanuma Y, Kiyosawa K. Another cause of autoimmune hepatitis. Hepatology 2010; 52:389.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 3663 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H7\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">CLASSIFICATION</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Type 1 autoimmune hepatitis</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Type 2 autoimmune hepatitis</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Overlap syndromes</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H595256676\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H19572391\" id=\"outline-link-H19572391\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"GAST/3663|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/65135\" class=\"graphic graphic_table\">- Classification of autoantibodies in autoimmune hepatitis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-hepatitis-variants-definitions-and-treatment\" class=\"medical medical_review\">Autoimmune hepatitis variants: Definitions and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-hepatitis-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Autoimmune hepatitis: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-hepatitis-pathogenesis\" class=\"medical medical_review\">Autoimmune hepatitis: Pathogenesis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-hepatitis-serologic-markers\" class=\"medical medical_review\">Autoimmune hepatitis: Serologic markers</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-hepatitis-treatment\" class=\"medical medical_review\">Autoimmune hepatitis: Treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-spectrum-of-antineutrophil-cytoplasmic-autoantibodies\" class=\"medical medical_review\">Clinical spectrum of antineutrophil cytoplasmic autoantibodies</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=autoimmune-hepatitis-beyond-the-basics\" class=\"medical medical_patient\">Patient education: Autoimmune hepatitis (Beyond the Basics)</a></li></ul></div></div>","javascript":null}